Perspectives on treating hepatitis C infection in the liver transplantation setting

Current Opinion in Organ Transplantation

Volumn 21, Issue 2, 2016, Pages 111-119

  Chen, Tianyan ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cirrhosis; direct acting antivirals; ribavirin; survival; sustained virological response

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

ANTIVIRAL THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; RECURRENT VIRUS INFECTION; REVIEW; RISK REDUCTION; SURVIVAL; TREATMENT RESPONSE; VIRAL CLEARANCE; COMPLICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; RECURRENT DISEASE; VIROLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE;

EID: 84960375005     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000288     Document Type: Review

References (44)

1. World Health Organization. Hepatitis C. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html [Accessed 15 December 2015
2. Kima WR, Stocka PG, Smitha JM, et al. OPTN/SRTR 2011 annual data report: liver. Am J Transplant 2013; 13(Suppl 1): 73-102.
3. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204.
4. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in postliver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007; 13: 719-724.
5. Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant 2010; 15: 301-309.
6. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-1494.
7. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62: 932-954.
8. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
9. Tekin F, Gunsar F, Karasu Z, et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27: 1081-1085.
10. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107 e1.
11. Donato MF, Monico S, Malinverno F, et al. Bridging all oral DAA therapy from wait time to postliver transplant to improve HCV eradication?. Liver Inter 2015; 35: 1-4.
12. Saxena V, Nyberg LM, Dasgupta A, et al. Hepatitis C virus (HCV) eradication in patients with varying severity of cirrhosis: impact on portal hypertensive complications, liver transplant (LT) and death. Hepatology 2015; 62(Suppl 1): 1099A.
13. Coilly A, Pageaux G, Hous-sel-Debry P, et al. Improving liver function and delisting of patients await-ing liver transplantation for HCV cirrhosis: do we ask too much to DAA?. Hepatology 2015; 62: 254A-258A.
14. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62: 715-725.
15. Modi AA, Nazario H, Trotter JF, et al. Safety and efficacy of simeprevirplus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transpl 2015. doi: 10.1002/lt.24324.
16. Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015; 61: 1793-1797.
17. Gane EJ, Manns M, McCaughan G, et al. High efficacy of ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: combined efficacy from the SOLAR-1 and SOLAR-2 trials. Hepatology 2015; 62(Suppl 1): 722A.
18. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J Hepatol 2015; 62: S261-S262.
19. Jacobson IM, Poordad F, Firpi-Morell R, et al. O008: Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child-pugh class B cirrhosis (C-salt part A). J Hepatol 2015; 62: S193-S194.
20. Curry MP, Oleary J, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618-2628.
21. Welzel TM, Nelson DR, Morelli G, et al. Safety and efficacy of sofosbuvir and ribavirin for the treatment of HCV genotype 2 and 3: results of the HCVTARGET study. Hepatology 2015; 62(Suppl 1): 727-728.
22. Welzel TM, Petersen J, Ferenci P, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program. Hepatology 2015; 62(Suppl 1): 225A.
23. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1- patients with end-stage renal disease on hemodialysis or GFR30 ml/min Liver Inter 2015 doi 10.1111/liv.13025
24. Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based directacting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond) 2015; 47: 924-929.
25. Samuel D, Manns M, Forns X, et al. Ledipasvir/sofosbuvir with ribavirin is safe in 600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials. J Hepatol 2015; 62: S620-S621.
26. Hezode C, De Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology 2015; 62(Suppl 1): 314A.
27. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 2015. pii: S0168-8278(15)00792-8.
28. Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016; 64: 234-238.
29. Aqel BA, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62: 1004-1012.
30. Mantry PS, Hanson J, Trinh R, et al. Ombitasvir/paritaprevir/r and dasabuvir with ribavirin for HCV genotype 1 patients with decompensated cirrhosis. Hepatology 2015; 62(Suppl 1): 568A-569A.
31. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687.
32. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9.
33. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687.
34. Bzowej N, Nelson D, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-538.
35. Fontana RJ, Poordad F, Schiff ER, et al. Improvement in liver disease parameters following treatment with daclatasvir sofosbuvir and ribavirin in patients with chronic HCV infection and advanced cirrhosis. Hepatology 2015; 62(Suppl 1): 558A.
36. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-659.
37. Brown RS Jr, Oleary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCVTARGET. Liver Transpl 2016; 22: 24-33.
38. Kwo PY, Mantry P, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382.
39. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatmentnaive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386: 1537-1545.
40. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 2015; 15: 1313-1322.
41. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117.
42. Herzer K, Welzel TM, Ferenci P, et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: Interim results of a mul-Ticenter compassionate use program. Hepatology 2015; 62(Suppl 1): 341A.
43. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858.
44. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for posttransplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46: 923-927.